News

Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...

Researchers conducted an information theoretic network meta-analysis to rank treatment regimens for hormone receptor-positive, ERBB2-negative metastatic breast cancer by their comparative effectiveness.

When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.

Use of a health system specialty pharmacy may be associated with a lower health care cost, according to a retrospective cohort study that examined Medicare Advantage beneficiaries' medical and pharmacy claims from 2018 and 2019.

The administration of oral etoposide at a dose of 50 mg/m2 showed fairish oncologic outcomes with manageable toxicity among patients with recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

In patients with multiple myeloma, daratumumab is utilized more frequently than the FDA-recommended dosing, which may lead to higher treatment costs.

When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.

In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.

Findings from a recent study suggest that even among the highest-quality hospitals, dually eligible patients who receive cancer surgery may have poorer outcomes and higher spending.

Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...